Towards Low Cost Coupling Structures for Short-Distance Optical Interconnections

The performance of short distance optical interconnections in general relies very strongly on coupling structures, since they will determine the overall efficiency of the system to a large extent. Different configurations can be considered and a variety of manufacturing technologies can be used. We present two different discrete and two different integrated coupling components which can be used to deflect the light beam over 90 degrees and can play a crucial role when integrating optical interconnections in printed circuit boards. The fabrication process of the different coupling structures is discussed and experimental results are shown. The main characteristics of the coupling structures are given. The main advantages and disadvantages of the different components are discussed

Evaluación de tres especies forrajeras perennes de crecimiento estival, medidas mediante variaciones de peso en novillos en pastoreo

A los efectos de corregir valores de calidad del forraje en la dieta (que determinan bajas ganancias de peso) en los rodeos que utilizan el pasto llorón (Eragrostis curvula) durante los períodos primavero-estivales y otros otoño invernales, se analizan especies alternativas que logran tener mejor calidad de forraje en verano, otoño y como diferido respecto del pasto llorón. Las especies Panicum coloratoum cv. Verde (mijo perenne), Eragrostis sueperba cv. Palar y Panicum. virgatum Alama se evaluaron en un ensayo a campo, realizado en la Facultad de Agronomía de la UNLPam, con novillos británicos en pastoreo durante el período 1/12/1998 al 7/1/99. Se midieron variaciones de peso en novillos mediante pesadas cada 15 días y disponibilidades de las diferentes parcelas a la entrada y salida de los animales a las mismas. No se encontraron diferencias significativas respecto a los pesos iniciales, como así tampoco diferencias significativas en las ganancias diarias de peso de los animales alimentados con las tres especies en estudio. Estos resultados de ganancias de peso pueden deberse a un período demasiado corto de evaluación. Este ensayo debió de detenerse por la ocurrencia de una marcada sequía primaveral que determinó condiciones de baja humedad en el perfil del suelo para el aprovechamiento de las especies durante la primavera y verano; como consecuencia, la disponibilidad de forraje fue limitante de la performance animal.Director: Ing. Agr. Néstor Stritzler, Cátedra de Nutrición Animal.Ca-Director: Ing. Agr. Carlos M. Ferri, Cátedra de Forrajicultura y Manejo de Pasturas

N6L pseudopeptide interferes with nucleophosmin protein-protein interactions and sensitizes leukemic cells to chemotherapy.

Abstract NPM1 is a multifunctional nucleolar protein implicated in several processes such as ribosome maturation and export, DNA damage response and apoptotic response to stress stimuli. The NPM1 gene is involved in human tumorigenesis and is found mutated in one third of acute myeloid leukemia patients, leading to the aberrant cytoplasmic localization of NPM1. Recent studies indicated that the N6L multivalent pseudopeptide, a synthetic ligand of cell–surface nucleolin, is also able to bind NPM1 with high affinity. N6L inhibits cell growth with different mechanisms and represents a good candidate as a novel anticancer drug for a number of malignancies of different histological origin. In this study we investigated whether N6L treatment could drive antitumor effect in acute myeloid leukemia cell lines. We found that N6L binds NPM1 at the N-terminal domain, co-localizes with cytoplasmic, mutated NPM1, and interferes with its protein-protein associations. N6L toxicity appears to be p53 dependent but interestingly, the leukemic cell line harbouring the mutated form of NPM1 is more resistant to treatment, suggesting that NPM1 cytoplasmic delocalization confers protection from p53 activation. Moreover, we show that N6L sensitizes AML cells to doxorubicin and cytarabine treatment. These studies suggest that N6L may be a promising option in combination therapies for acute myeloid leukemia treatment

Synthesis and Investigation of a Radioiodinated F3 Peptide Analog as a SPECT Tumor Imaging Radioligand

A radioiodinated derivative of the tumor-homing F3 peptide, (N-(2-{3-[125I]Iodobenzoyl}aminoethyl)maleimide-F3Cys peptide, [125I]IBMF3 was developed for investigation as a SPECT tumor imaging radioligand. For this purpose, we custom synthesized a modified F3 peptide analog (F3Cys) incorporating a C-terminal cysteine residue for site-specific attachment of a radioiodinated maleimide conjugating group. Initial proof-of-concept Fluorescence studies conducted with AlexaFluor 532 C5 maleimide-labeled F3Cys showed distinct membrane and nuclear localization of F3Cys in MDA-MB-435 cells. Additionally, F3Cys conjugated with NIR fluorochrome AlexaFluor 647 C2 maleimide demonstrated high tumor specific uptake in melanoma cancer MDA-MB-435 and lung cancer A549 xenografts in nude mice whereas a similarly labeled control peptide did not show any tumor uptake. These results were also confirmed by ex vivo tissue analysis. No-carrier-added [125I]IBMF3 was synthesized by a radioiododestannylation approach in 73% overall radiochemical yield. In vitro cell uptake studies conducted with [125I]IBMF3 displayed a 5-fold increase in its cell uptake at 4 h when compared to controls. SPECT imaging studies with [125I]IBMF3 in tumor bearing nude mice showed clear visualization of MDA-MB-435 xenografts on systemic administration. These studies demonstrate a potential utility of F3 peptide-based radioligands for tumor imaging with PET or SPECT techniques

Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice

<p>Abstract</p> <p>Background</p> <p>The importance of cell-surface nucleolin in cancer biology was recently highlighted by studies showing that ligands of nucleolin play critical role in tumorigenesis and angiogenesis. By using a specific antagonist that binds the C-terminal tail of nucleolin, the HB-19 pseudopeptide, we recently reported that HB-19 treatment markedly suppressed the progression of established human breast tumor cell xenografts in the athymic nude mice without apparent toxicity.</p> <p>Methods</p> <p>The <it>in vivo </it>antitumoral action of HB-19 treatment was assessed on the spontaneous development of melanoma in the RET transgenic mouse model. Ten days old RET mice were treated with HB-19 in a prophylactic setting that extended 300 days. In parallel, the molecular basis for the action of HB-19 was investigated on a melanoma cell line (called TIII) derived from a cutaneous nodule of a RET mouse.</p> <p>Results</p> <p>HB-19 treatment of RET mice caused a significant delay in the onset of cutaneous tumors, several-months delay in the incidence of large tumors, a lower frequency of cutaneous nodules, and a reduction of visceral metastatic nodules while displaying no toxicity to normal tissue. Moreover, microvessel density was significantly reduced in tumors recovered from HB-19 treated mice compared to corresponding controls. Studies on the melanoma-derived tumor cells demonstrated that HB-19 treatment of TIII cells could restore contact inhibition, impair anchorage-independent growth, and reduce their tumorigenic potential in mice. Moreover, HB-19 treatment caused selective down regulation of transcripts coding matrix metalloproteinase 2 and 9, and tumor necrosis factor-α in the TIII cells and in melanoma tumors of RET mice.</p> <p>Conclusions</p> <p>Although HB-19 treatment failed to prevent the development of spontaneous melanoma in the RET mice, it delayed for several months the onset and frequency of cutaneous tumors, and exerted a significant inhibitory effect on visceral metastasis. Consequently, HB-19 could provide a novel therapeutic agent by itself or as an adjuvant therapy in association with current therapeutic interventions on a virulent cancer like melanoma.</p